journal article·2010-08

Solvent‐free biodegradable scleral plugs providing sustained release of vancomycin, amikacin, and dexamethasone—An in vivo study

Yi‐Jie Peng, Yi‐Chuan Kau, Chin‐Wei Wen, Kuo‐Sheng Liu, Shih‐Jung Liu

Publisher page

Abstract

Abstract Delivering effective drugs at sufficiently high concentrations to the area of infection is a standard treatment for infectious disease, such as endophthalmitis. This is currently done by empirical trans pars plana intravitreal injection of both antibiotics directed against gram‐positive and gram‐negative microorganisms and steroids. However, injections by needles repeatedly may increase the risks of intraocular infection and hemorrhage, as well as retinal detachment. This article explores the alternative of using biodegradable polymers as scleral plugs for a long‐term drug release in vivo. To manufacture plugs, poly(lactide‐glycolide) copolymers were first mixed with vancomycin, amikacin, and dexamethasone. The mixture was compressed and sintered at 55°C to form scleral plugs 1.4 mm in diameter. Biodegradable scleral plugs released high concentrations of antibiotics (well above the minimum inhibitory concentrations, MIC) and steroids in vivo for the period of time needed to treat intraocular infection. In addition, no major complications such as infectious or sterile endophthalmitis, retinal detachment, ocular phthisis, or uvea protrusion at sclerotomy site were observed throughout the experiment. The sclerotomy wound healed after total degradation of the scleral implants without leakage or local necrosis. Antibiotic/steroid‐impregnated biodegradable scleral plugs may have a potential role in the treatment of various intraocular infections. © 2010 Wiley Periodicals, Inc. J Biomed Mater Res 2010
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Ocular Infections and Treatments · Intraocular Surgery and Lenses · Ocular Diseases and Behçet’s Syndrome

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (28)

Show source-provided references
1. 10.1001/archopht.1995.0110012000900110.1001/archopht.1995.01100120009001 ↗
2. 10.1016/S0002-9394(14)71959-210.1016/S0002-9394(14)71959-2 ↗
3. 10.1097/00006982-199515050-0001010.1097/00006982-199515050-00010 ↗
4. 10.1016/S0896-1549(02)00034-210.1016/S0896-1549(02)00034-2 ↗
5. 10.1002/jbm.82026120310.1002/jbm.820261203 ↗
6. 10.1016/j.ijpharm.2008.11.02410.1016/j.ijpharm.2008.11.024 ↗
7. 10.1016/S0025-7125(16)31451-110.1016/S0025-7125(16)31451-1 ↗
8. 10.1128/AAC.14.5.78610.1128/AAC.14.5.786 ↗
9. 10.1016/0168-3659(90)90152-J10.1016/0168-3659(90)90152-J ↗
10. 10.3109/1745367950899556310.3109/17453679508995563 ↗
11. 10.1111/j.2042-7158.1994.tb03890.x10.1111/j.2042-7158.1994.tb03890.x ↗
12. 10.1007/s00417005003110.1007/s004170050031 ↗
13. 10.1002/1097-4636(20000915)51:4<635::AID-JBM11>3.0.CO;2-O10.1002/1097-4636(20000915)51:4<635::AID-JBM11>3.0.CO;2-O ↗
14. 10.1016/S0169-409X(01)00192-210.1016/S0169-409X(01)00192-2 ↗
15. 10.1016/j.jconrel.2005.03.01010.1016/j.jconrel.2005.03.010 ↗
16. An in vitro study on the compatibility and concentrations of combinations of vancomycin, amikacin, and dexamethasone in human vitreous10.1038/sj.eye.6702321 ↗
17. 10.1007/s10439-005-8974-710.1007/s10439-005-8974-7 ↗
18. Antibiotic‐impregnated beads. Part I: Bead implantation versus systemic therapy
19. 10.1002/jbm.82026110610.1002/jbm.820261106 ↗
20. 10.1136/bjo.83.9.105010.1136/bjo.83.9.1050 ↗
21. 10.1097/00006982-200106000-0000210.1097/00006982-200106000-00002 ↗
22. 10.1001/archopht.1986.0105015006702810.1001/archopht.1986.01050150067028 ↗
23. 10.1001/archopht.1991.0108007005803510.1001/archopht.1991.01080070058035 ↗
24. 10.1016/0002-9394(85)90792-510.1016/0002-9394(85)90792-5 ↗
25. Corticosteroid treatment of laser retinal damage affects prostaglandin E2 response
26. 10.1038/278456a010.1038/278456a0 ↗
27. 10.1002/jps.1040210.1002/jps.10402 ↗
28. 10.1001/archopht.1984.0104003047002910.1001/archopht.1984.01040030470029 ↗